Wednesday, May 25, 2022 7:10:12 PM
In case you forgot "Shorter dosing regimens are important as they reduce the risks from Intravenous therapy complications, reduce costs such as reduced hospital stays and clinic visits, and can help reduce the emergence of antibiotic resistance through a combination of a quick bacterial kill, shorter duration of treatment, and increased patient compliance." https://en.wikipedia.org/wiki/Brilacidin
In case you forgot
• Single-dose brilacidin was safe and well tolerated in a phase 2b ABSSSI study
• Reduction in total dose decreases the frequency, severity, and duration of adverse
events, vs. phase 2a study
• Blood pressure events low in 0.6 mg/kg single-dose regimen, similar to or better than daptomycin (active control)
• There were no treatment-related SAEs or hypertension-related SAEs
• Numbness/Tingling mild, transient, and decreased in frequency and severity, vs.
phase 2a study
In case you forgot the US FDA said it was okay to give Brilacidin to humans in three more trials after the Daptomycin trial. The US FDA said it was okay to give Brilacidin to humans in the mouth and in the stomach and in the blood. The US FDA also said it was okay to give Brilacidin to humans super sick with the new virus with Compassionate Use. Maybe you forgot.
You can say as many times as you want Brilacidin is an unsafe dangerous drug. But the US FDA does not agree with you. If you know anything about pharmaceuticals the US FDA is the best drug safety judge in the world.
Be careful for the magnet that will stick to your arm where you received the virus vaccine. Pfft.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM